Clinical trials: Inadequate Glycaemic Control
Diabetes Mellitus, Type 2
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
The aim of this study is to investigate the efficacy and safety of two doses (high and low) of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) and insufficient glycaemic control.
- Trial name
- NCT01649297
- Testing
- empagliflozin (low dose qd), Empagliflozin (high dose qd), empagliflozin (high dose bid)
- Where
- 139 sites in United States, Australia and 16 more
- Volunteers
- 983 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Effect of Repaglinide Versus Metformin Treatment in Non-Obese Patients With Type-2-Diabetes
Aim: The United Kingdom Prospective Diabetes Study (UKPDS) showed a reduction in cardiovascular events in obese patients with type-2-diabetes treated with metformin compared with other hypoglycaemic treatments with no difference…
- Trial name
- NCT00118963
- Testing
- Metformin, Insulin BIAsp30 (Novolog 70/30), Repaglinide
- Where
- Denmark
- Volunteers
- 102 people
- Sponsor
- Steno Diabetes Center Copenhagen
Type 2 Diabetes (T2DM)
TriGlytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Diabetes and Inadequate Glycaemic Control Despite Metformin Therapy
This Phase 2a, randomized, double-blind, active-controlled study will evaluate the safety, tolerability, and preliminary efficacy of TriGlytza®-01 compared with metformin in adults with Type 2 diabetes inadequately controlled…
- Trial name
- RESILIENCE-2a (NCT07139405)
- Testing
- Metformin XR, Celecoxib, Valsartan
- Where
- 3 sites in Australia
- Volunteers
- 48 people
- Sponsor
- Myopharm Limited
Type 2 Diabetes
Patients With Type 2 Diabetes Mellitus With Insufficient Glycaemic Control Despite Treatment With Metformin Alone or Metformin in Combination With a Sulfonylurea
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 (10 mg, 25 mg / once daily) compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus…
- Trial name
- NCT01257334
- Testing
- BI 10773
- Where
- Taiwan
- Volunteers
- 1,390 people
- Sponsor
- Taipei Medical University WanFang Hospital
Diabetes Mellitus, Type 2
Linagliptin Add-on to Insulin Background Therapy
To evaluate the efficacy and safety of linagliptin compared to placebo when added on to insulin therapy alone or in combination with metformin in Chinese patients with type 2 diabetes mellitus with insufficient glycaemic control
- Trial name
- NCT02897349
- Testing
- linagliptin, background therapy
- Where
- 25 sites in China
- Volunteers
- 206 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus, High HbA1c Level
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
This study intends to compare the efficacy and safety of dapagliflozin versus placebo in patients with type 2 diabetes who have inadequate glycaemic control on a background combination of metformin and sulfonylurea.
- Conditions
- Type 2 Diabetes Mellitus, High HbA1c Level, Inadequate Glycaemic Control
- Trial name
- NCT01392677
- Testing
- dapagliflozin
- Where
- 42 sites in Canada, Czechia and 4 more
- Volunteers
- 311 people
- Sponsor
- AstraZeneca